PROFOUND MEDICAL CORP (PRN.CA) Stock Price, Forecast & Analysis
Canada - TSX:PRN - CA74319B5027 - Common Stock
PRN.CA Key Statistics, Chart & Performance
The current stock price of PRN.CA is 8.36 CAD. In the past month the price increased by 12.06%. In the past year, price decreased by -18.83%.
PRN.CA Latest News, Press Relases and Analysis
PRN.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| MIR.CA | MEDMIRA INC | N/A | 60.66M | ||
| TLT.CA | THERALASE TECHNOLOGIES INC | N/A | 52.03M | ||
| CNVI.CA | CONAVI MEDICAL CORP | N/A | 45.28M | ||
| PINK.CA | PERIMETER MEDICAL IMAGING AI | N/A | 29.10M | ||
| ASG.CA | AURORA SPINE CORP | N/A | 24.71M | ||
| MDX.CA | MEDX HEALTH CORP | N/A | 20.07M | ||
| NSCI.CA | NANALYSIS SCIENTIFIC CORP | N/A | 19.52M | ||
| VPT.CA | VENTRIPOINT DIAGNOSTICS LTD | N/A | 17.61M | ||
| THRM.CA | THERMA BRIGHT INC | N/A | 4.26M | ||
| VER-H.CA | VERISANTE TECHNOLOGY INC | N/A | 439.40K | ||
| IDL.CA | IMAGING DYNAMICS CO LTD | N/A | 413.20K | ||
| VVTM.CA | VVT MED INC | N/A | 20.71M |
Related stock screener links
About PRN.CA
Company Profile
Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Company Info
PROFOUND MEDICAL CORP
2400 Skymark Ave Unit 6
Mississauga ONTARIO L4W 5K5 CA
CEO: Arun Menawat
Employees: 131
Phone: 16474761350
PROFOUND MEDICAL CORP / PRN.CA FAQ
What does PROFOUND MEDICAL CORP do?
Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
What is the current price of PRN stock?
The current stock price of PRN.CA is 8.36 CAD. The price decreased by -2.79% in the last trading session.
Does PRN stock pay dividends?
PRN.CA does not pay a dividend.
What is the ChartMill rating of PROFOUND MEDICAL CORP stock?
PRN.CA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists PRN stock?
PRN.CA stock is listed on the Toronto Stock Exchange exchange.
What is the Price/Earnings (PE) ratio of PROFOUND MEDICAL CORP (PRN.CA)?
PROFOUND MEDICAL CORP (PRN.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.05).
Can you provide the market cap for PROFOUND MEDICAL CORP?
PROFOUND MEDICAL CORP (PRN.CA) has a market capitalization of 251.80M CAD. This makes PRN.CA a Micro Cap stock.
PRN.CA Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to PRN.CA. When comparing the yearly performance of all stocks, PRN.CA is a bad performer in the overall market: 85.43% of all stocks are doing better.
PRN.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PRN.CA. While PRN.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
PRN.CA Financial Highlights
Over the last trailing twelve months PRN.CA reported a non-GAAP Earnings per Share(EPS) of -2.05. The EPS decreased by -19.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.01% | ||
| ROE | -103.75% | ||
| Debt/Equity | 0.12 |
PRN.CA Forecast & Estimates
6 analysts have analysed PRN.CA and the average price target is 15.56 CAD. This implies a price increase of 86.06% is expected in the next year compared to the current price of 8.36.
For the next year, analysts expect an EPS growth of -38.2% and a revenue growth 51.68% for PRN.CA